Fibrin sealants in supporting surgical techniques: Strength in factor XIII

Cardiovascular Surgery

Volumn 11, Issue SUPPL. 1, 2003, Pages 13-16

  Phillips, Martin ^a   Dickneite, G ^b   Metzner, H ^b  

^a Aventis Behring   (United States)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Blood coagulation; Drug combinations; Factor XIII; Fibrin sealant; Hemostasis; Metabolism; Thrombin; Wound healing

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 13; ENZYME; FIBRIN; FIBRIN GLUE;

BLEEDING; BLOOD BANK; BLOOD CLOTTING; BLOOD VESSEL GRAFT; CROSS LINKING; FIBRIN CLOT; FIBRINOLYSIS; HEMOSTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SURGICAL TECHNIQUE; WOUND HEALING;

EID: 0038376548     PISSN: 09672109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-2109(03)00066-8     Document Type: Article

References (30)

1. Gibble J.W., Ness P.M. Fibrin glue: the perfect operative sealant? Transfusion. 30:1990;741-747.
2. Sierra D.H. Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications. Journal of Applied Biomaterials. 7:1993;309-352.
3. Tock B., Drohan W., Hess J., et al. Haemophilia and advanced fibrin sealant technologies. Haemophilia. 4:1998;449-455.
4. Dickneite G., Metzner H., Nicolay U. Prevention of suture hole bleeding in a pig vascular model using fibrin sealant - benefits of factor XIII. Journal of Surgical Research. 93:2000;201-205.
5. Mackie I.J. The biology of hemostasis and thrombosis. Weatherall D.J., Ledingham J.G.G., Warrell D.A. Oxford Textbook of Medicine. 3rd edn: 1996;3613-3627 Oxford University Press, New York.
6. Katona E., Haramura G., Karpati L., et al. A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thrombosis and Hemostasis. 83:2000;268-273.
7. Brackmann H.H., Egbring R., Ferster A., et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thrombosis and Hemostasis. 74:1995;622-625.
8. Muszbek L., Yee V.C., Hevessy Z. Blood coagulation factor XIII: structure and function. Thrombosis Research. 94:1999;271-305.
9. Yee V.C., Pedersen L.C., Trong I.L., et al. Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII. Proceedings of the National Academy of Sciences of the United States of America. 91:1994;7296-7300.
10. McDonagh J., Fukue H. Determinants of substrate specificity for factor XIII. Seminars in Thrombosis and Hemostasis. 22:1996;369-376.
11. Shen L.L., Hermans J., McDonagh J., et al. Effects of calcium ion and covalent crosslinking on formation and elasticity of fibrin gels. Thrombosis Research. 6:1975;255-265.
12. Shen L., Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. Journal of Clinical Investigation. 71:1983;1336-1341.
13. Ryan E.A., Mockros L.F., Stern A.M., et al. Influence of a natural and a synthetic inhibitor of Factor XIIIa on fibrin clot rheology. Biophysical Journal. 77:1999;2827-2836.
14. Francis C.W., Marder V.J. Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. Blood. 71:1988;1361-1365.
15. Uchino R., Cardinali M., Chung S.I. Regulation of extravascular fibrinolysis by factor XIII. Fibrinolysis. 5:1991;93-98.
16. Edwards M.W., De Bang E., Strout J., et al. Recombinant factor XIII supplemented clots resist lysis by plasmin and leucocyte elastase. Fibrinolysis. 7:1993;211-216.
17. Sakata Y., Aoki N. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. Journal of Clinical Investigation. 69:1982;536-542.
18. Brown L.F., Lanir N., McDonagh J., et al. Fibroblast migration in fibrin gel matrices. American Journal of Pathology. 142:1993;273-283.
19. Hansen M.S. Fibronectin and coagulation factor XIII increases blood platelet adhesion to fibrin. Thrombosis Research. 34:1984;551-556.
20. Bale M.D., Mosher D.F. Thrombospondin is a substrate for blood coagulation factor XIIIa. Biochemistry. 25:1986;5667-5673.
21. Cohen I., Blankenberg T.A., Borden D., et al. Factor XIIIa-catalyzed cross-linking of platelet and muscle actin. Regulation by nucleotides. Biochemica et Biophysica Acta. 628:1980;365-375.
22. Francis R.T., McDonagh J., Mann K.G. Factor V is a substrate for the transamidase factor XIIIa. Journal of Biological Chemistry. 261:1986;9787-9792.
23. Hada M., Kaminski M., Bockenstedt P., et al. Covalent crosslinking of von Willebrand factor to fibrin. Blood. 68:1986;95-101.
24. Board P.G., Losowsky M.S., Miloszewski K.J. Factor XIII: inherited and acquired deficiency. Blood Reviews. 7:1993;229-242.
25. Anwar R., Miloszewski K.J. Factor XIII deficiency. British Journal of Haematology. 107:1999;468-484.
26. Reiner A.P. Fibrin glue increasingly popular for topical surgical hemostasis. Laboratory Medicine. 30:1999;189-193.
27. Clark D.B., Drohan W.N., Miekka S.I., et al. Strategy for purification of coagulation factor concentrates. Annals of Clinical Laboratory Science. 19:1989;196-207.
28. Holland P.V. Viral infections and the blood supply. New England Journal of Medicine. 334:1996;1734-1735.
29. Glidden P.F., Malaska C., Herring S.W. Thromboelastograph assay for measuring the mechanical strength of fibrin sealant clots. Clinical and Applied Thrombosis and Hemostasis. 6:2000;226-233.
30. Milne A.A., Murphy W.G., Reading S.J., et al. A randomised trial of fibrin sealant in peripheral vascular surgery. Vox Sanguinis. 70:1996;210-212.